Clinical Trial Update: Hizentra® in Inflammatory Neuropathies - pHeNIx Study

View source ↗

Summary

A pHeNIx clinical trial is evaluating Hizentra for Chronic Inflammatory Demyelinating Polyneuropathy and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Hizentra (subcutaneous immunoglobulin (IgG))

Snippet

Sponsor: CSL Behring | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy | Status: RECRUITING